PI3Kδ inhibitor 52

CAS No. 1911564-39-0

PI3Kδ inhibitor 52 ( —— )

Catalog No. M12995 CAS No. 1911564-39-0

A potent, selective, and efficacious PI3Kδ inhibitor with IC50 of 1.7 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 222 Get Quote
10MG 357 Get Quote
25MG 597 Get Quote
50MG 851 Get Quote
100MG 1152 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    PI3Kδ inhibitor 52
  • Note
    Research use only, not for human use.
  • Brief Description
    A potent, selective, and efficacious PI3Kδ inhibitor with IC50 of 1.7 nM.
  • Description
    A potent, selective, and efficacious PI3Kδ inhibitor with IC50 of 1.7 nM, >100-fold selectivitity over PI3Kγ/α/β; shows potent activity in mouse arthritis models.
  • Synonyms
    ——
  • Pathway
    PI3K/Akt/mTOR signaling
  • Target
    PI3K
  • Recptor
    PI3K
  • Research Area
    Inflammation/Immunology
  • Indication
    ——

Chemical Information

  • CAS Number
    1911564-39-0
  • Formula Weight
    471.44
  • Molecular Formula
    C22H20F3N7O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CC(=O)N1CCN(C(=O)C1(C)C)C2=C(C=CC(=C2)C3=CC(=C4N3N=CN=C4N)C(F)(F)F)C#N
  • Chemical Name
    2-(4-acetyl-3,3-dimethyl-2-oxopiperazin-1-yl)-4-(4-amino-5-(trifluoromethyl)pyrrolo[2,1-f][1,2,4]triazin-7-yl)benzonitrile

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Liu Q, et al. J Med Chem. 2017 Jun 22;60(12):5193-5208.
molnova catalog
related products
  • Tenalisib (RP6530)

    Tenalisib (RP6530) is a novel, potent, and selective PI3Kδ and PI3Kγ inhibitor with IC50 values of 25 and 33 nM, respectively.

  • GSK-2269557

    GSK-2269557 is a highly potent and selective inhibitor of PI3Kδ (pKi=9.9).

  • BYL-719

    Alpelisib (BYL-719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.